News

Diagnostic chip radios results
Enlarge image

ResearchSwitzerland

Diagnostic chip radios results

21.03.2013 - EPFL scientists have developed a tiny, portable personal blood testing implant that sends diagnostic data through mobile phone network.

A tiny subcutaneously implanted blood testing chip can analyse several diagnostic blood parameters and then transmit the results directly to a doctor's computer. The device, developed by researchers at Swiss EPFL in Lausanne is good news for patients with chronic illness such as diabetes or those undergoing chemotherapy, whose blood needs to be monitored permanently. The implant offers an alternative to non-invasive sensors under development, which measure through the skin.

Each of the 5 sensor's surfaces can be covered with an enzyme that allows to detect a blood metabolite or with an antibody that captures specific protein markers.  The few cubic centimetre-large chip's sensors can trace blood glucose, proteins, ATP or organic acids such as lactate simultaneously, Giovanni de Micheli and Sandro Carrara announced at DATE 13, Europe's largest electronics conference.

Potentially, we could detect just about anything," explains De Micheli. "But the enzymes have a limited lifespan." The enzymes currently being tested are good for about a month and a half; that's already long enough for many applications.." After the measurement, the implant emits radio waves over a safe frequency. The patch collects the data and transmits them via Bluetooth to a mobile phone, which then sends them to the doctor over the cellular network.  The implant could be particularly useful in chemotherapy applications.

Currently, oncologists use occasional blood tests to evaluate their patients' tolerance to a particular treatment dosage. Additionally, in patients with chronic disorders, the implants could send alerts even before symptoms emerge, and anticipate the need for medication. The researchers hope the system will be commercially available within 4 years.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/diagnostic-chip-radios-results.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014